Lataa...
Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation
• Molecular testing may play a role in the determination of targeted therapy treatment options. • Targeted therapy provides treatment options for recurrent cervical cancer. • MEK inhibitor is a treatment option for recurrent cervical cancer in a patient with KRAS mutation.
Tallennettuna:
| Julkaisussa: | Gynecol Oncol Rep |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Elsevier
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4434143/ https://ncbi.nlm.nih.gov/pubmed/26075998 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gore.2014.09.003 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|